The most important current gap in the evidence base is the lack of direct evidence on clinical outcomes resulting from prescribing decisions guided by SLCO1B1 rs4149056 genotyping and the lack, to date, of studies investigating the clinical validity of combining SLCO1B1 genotype with other risk factors for myopathy such as those included in the Qstatin risk score. Here, SLCO1B1 is linked to myopathy.